Alpine Immune Sciences, Inc. ALPN announced that it has entered into a collaboration and supply agreement with pharma giant Merck MRK for conducting an immuno-oncology study. The study – NEON-2 – ...
Alpine Immune Sciences Inc (NASDAQ:ALPN) presents promising clinical data for povetacicept at ASN Kidney Week. Successful $150 million equity offering to fuel development activities into 2026.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory ...
In this article we are going to use hedge fund sentiment as a tool and determine whether Alpine Immune Sciences, Inc. (NASDAQ:ALPN) is a good investment right now. We like to analyze hedge fund ...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don’t make them change their opinion towards ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results